AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Jazz Pharmaceuticals (JAZZ)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

135.94

-0.71 (-0.52%)

At close: Feb 21, 2025, 3:59 PM

136.01

0.05%

After-hours: Feb 21, 2025, 04:00 PM EST

undefined% (undefined)

Bid	127.1
Market Cap	8.22B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	7.06
PE Ratio (ttm)	19.25
Forward PE	n/a
Analyst	Buy

Ask	136.01
Volume	418,040
Avg. Volume (20D)	599,691
Open	134.65
Previous Close	136.65
Day's Range	134.58 - 137.37
52-Week Range	99.06 - 138.27
Beta	undefined

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2007

Employees 2,800

Stock Exchange NASDAQ

Ticker Symbol JAZZ

Website https://www.jazzpharma.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $174.5, which is an increase of 28.37% from the latest price.

Buy 85.71%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Jazz Pharmaceuticals is scheduled to release its earnings on Feb 25, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+1.02%

Jazz Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription

3 months ago

+6.75%

Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results. Needham reiterated a Buy rating on the stock.

News

2 days ago · zacks.com

Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some...

1 week ago · zacks.com

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

2 weeks ago · zacks.com

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago · seekingalpha.com

3 Biotech Stocks With Notable Insider Buying

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...

1 month ago · seekingalpha.com

3 Oversold Biotech Names

High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

2 months ago · seekingalpha.com

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise fac...

2 months ago · zacks.com

5 High ROE Stocks to Buy as Volatility Weighs on Markets

DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.

2 months ago · zacks.com

Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet

The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...

3 months ago · zacks.com

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.